Clavurox 250 Tablet: Each film coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic Acid 62.5 mg as diluted Potassium Clavulanate BP.
Clavurox 500 Tablet: Each film coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic Acid 125 mg as diluted Potassium Clavulanate BP.
Clavurox 70 ml Powder for Suspension: After reconstitution, each 5 ml suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic Acid 31.25 mg as diluted Potassium Clavulanate BP.
Cefuroxime is one of the bactericidal second generation cephalosporin antibiotics, which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. It is indicated for the treatment of infections caused by sensitive bacteria. Clavulanic Acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta lactamase enzymes. The presence of Clavulanic Acid in Cefuroxime & Clavulanic Acid formulations protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Adolescents and Adults:
Infection.
Dosage:
Duration (days).
Pharyngitis or Tonsillitis.
250 mg b.i.d.
10.
Acute Bacterial Maxillary Sinusitis.
250 mg b.i.d.
10.
Acute Bacterial Exacerbation of Chronic Bronchitis.
250-500 mg b.i.d.
10.
Secondary Bacterial Infections of Acute Bronchitis.
250-500 mg b.i.d.
5-10.
Community Acquired Pneumonia.
250-500 mg b.i.d.
5-10.
Complicated Skin & Skin-Structure Infections.
250-500 mg b.i.d.
10.
MDR Typhoid Fever.
500 mg b.i.d.
10-14.
Uncomplicated Urinary Tract Infection.
250 mg b.i.d.
7-10.
Uncomplicated Gonorrhea.
1000 mg once.
single dose.
Lyme Disease.
500 mg b.i.d.
20.
Paediatric patients (3 months to 12 years):
Infection.
Dosage:
Duration (days).
Pharyngitis or Tonsillitis.
20 mg/kg/day in two divided doses.
5-10.
Acute otitis media.
30 mg/kg/day in two divided doses.
10.
Acute bacterial maxillary sinusitis.
30 mg/kg/day in two divided doses.
10.
Community acquired pneumonia.
30 mg/kg/day in two divided doses.
5-10.
MDR Typhoid fever.
30 mg/kg/day in two divided doses.
10-14.
Complicated skin & skin-structure infections.
30 mg/kg/day in two divided.
Concomitant administration of Probenecid with Cefuroxime & Clavulanic Acid increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.
Overdosage Signs and symptoms: Overdosage of Cefuroxime & Clavulanic Acid can cause cerebral irritation leading to convulsions. Management: Serum levels of Cefuroxime & Clavulanic Acid can be reduced by haemodialysis and peritoneal dialysis.
During pregnancy: While all antibiotics should be avoided in the first trimester if possible. However, Cefuroxime & Clavulanic Acid can be safely used in later to treat urinary and other infections.
During lactation: Cefuroxime & Clavulanic Acid is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.
Cefuroxime & Clavulanic Acid should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.
Store at below 25°C in a dry place protected from light. Keep out of reach of children.